Publications

---

2026

• Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis
  March 19, 2026 by Tanner Michaelis
• ALS motor phenotypes: a revised 'OPM' classification
  March 17, 2026 by Thomas Meyer
• Impaired nucleocytoplasmic transport in SOD1-mediated ALS
  February 14, 2026 by Shirel Argueti-Ostrovsky

2025

• TDP-43 skein-like inclusions are formed by BAG3- and HSP70-guided co-aggregation with actin-binding proteins
  November 1, 2025 by Shan Lu
• Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases
  October 29, 2025 by Gang Wu
• TDP-43 loss induces cryptic polyadenylation in ALS/FTD
  October 21, 2025 by Sam Bryce-Smith
• Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis
  October 1, 2025 by Tanner Michaelis
• RNA triggers chronic stress during neuronal aging
  August 13, 2025 by Kevin Rhine
• Neuronal aging causes mislocalization of splicing proteins and unchecked cellular stress
  June 2, 2025 by Kevin Rhine
• Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics
  February 22, 2025 by Sarah Mizielinska

2024

• CK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis
  December 5, 2024 by Vivian I Ko
• Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data
  October 22, 2024 by Sara Saez-Atienzar
• Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis
  September 13, 2024 by Michael Benatar
• A framework for sharing of clinical and genetic data for precision medicine applications
  September 3, 2024 by Ahmed Elhussein
• Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
  July 26, 2024 by Leonard H van den Berg
• Author Correction: TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A
  June 18, 2024 by Anna-Leigh Brown
• Alternatively spliced ELAVL3 cryptic exon 4a causes ELAVL3 downregulation in ALS TDP-43 proteinopathy
  May 30, 2024 by Isabel Costantino
• CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation
  April 27, 2024 by Vivian I Ko
• The cycad genotoxin methylazoxymethanol, linked to Guam ALS/PDC, induces transcriptional mutagenesis
  February 21, 2024 by Bert M Verheijen
• Misfolded alpha-synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment
  January 25, 2024 by Richard Smith
• Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation
  November 23, 2023 by Jone López-Erauskin
• Temporal course of cognitive and behavioural changes in motor neuron diseases
  October 12, 2023 by Caroline A McHutchison

• CK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis
  December 5, 2024 by Vivian I Ko
• Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data
  October 22, 2024 by Sara Saez-Atienzar
• CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation
  April 27, 2024 by Vivian I Ko

2023

• TDP-43 skein-like inclusions are formed by BAG3- and HSP70-guided co-aggregation with actin-binding proteins
  November 1, 2025 by Shan Lu
• Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases
  October 29, 2025 by Gang Wu
• TDP-43 loss induces cryptic polyadenylation in ALS/FTD
  October 21, 2025 by Sam Bryce-Smith
• Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis
  October 1, 2025 by Tanner Michaelis
• RNA triggers chronic stress during neuronal aging
  August 13, 2025 by Kevin Rhine
• Neuronal aging causes mislocalization of splicing proteins and unchecked cellular stress
  June 2, 2025 by Kevin Rhine
• Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics
  February 22, 2025 by Sarah Mizielinska

• Genome-wide structural variant analysis identifies risk loci for non-Alzheimer's dementias
  June 30, 2023 by Karri Kaivola

2022

• Whole genome sequencing analysis reveals post-zygotic mutation variability in monozygotic twins discordant for amyotrophic lateral sclerosis
  December 15, 2022 by Gijs H P Tazelaar
• Radiogenomics of C9orf72 Expansion Carriers Reveals Global Transposable Element Derepression and Enables Prediction of Thalamic Atrophy and Clinical Impairment
  November 29, 2022 by Luke W Bonham
• NOS1AP is a novel molecular target and critical factor in TDP-43 pathology
  October 21, 2022 by Sara Cappelli
• Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
  September 21, 2022 by Timothy M Miller
• Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition
  September 8, 2022 by Shan Lu
• The lower motor neuron homunculus
  August 27, 2022 by John Ravits
• Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis
  July 1, 2022 by Florian Krach
• Nuclear RIPK1 promotes chromatin remodeling to mediate inflammatory response
  June 6, 2022 by Wanjin Li
• Cell environment shapes TDP-43 function with implications in neuronal and muscle disease
  April 6, 2022 by Urša Šušnjar
• TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A
  February 24, 2022 by Anna-Leigh Brown

2021

• Delivering Bad News in Amyotrophic Lateral Sclerosis: Proposal of Specific Technique ALS ALLOW
  January 7, 2022 by Wesleigh F Edwards
• Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders
  November 19, 2021 by Jonathan Gilley
• An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients
  November 8, 2021 by NeuroLINCS Consortium
• Nuclear depletion of RNA-binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis
  October 7, 2021 by Sandra Diaz-Garcia
• Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
  September 18, 2021 by Merit Cudkowicz
• Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis
  August 30, 2021 by Janel O Johnson
• TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination
  August 4, 2021 by Wan Yun Ho
• Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype
  April 12, 2021 by Frances Theunissen
• Nucleolar stress in C9orf72 and sporadic ALS spinal motor neurons precedes TDP-43 mislocalization
  February 16, 2021 by Olubankole Aladesuyi Arogundade
• Cross-Comparison of Human iPSC Motor Neuron Models of Familial and Sporadic ALS Reveals Early and Convergent Transcriptomic Disease Signatures
  December 31, 2020 by Ritchie Ho
• Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis
  December 3, 2020 by Katerina Placek
• Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis
  November 26, 2020 by Ramita Dewan
• ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation
  November 13, 2020 by Jin-Hui Hor

• Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis
  August 30, 2021 by Janel O Johnson
• Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis
  November 26, 2020 by Ramita Dewan

2020

• Preface: promoting research in PLS: current knowledge and future challenges
  February 19, 2021 by Hiroshi Mitsumoto
• Cross-Comparison of Human iPSC Motor Neuron Models of Familial and Sporadic ALS Reveals Early and Convergent Transcriptomic Disease Signatures
  December 31, 2020 by Ritchie Ho
• Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis
  December 3, 2020 by Katerina Placek
• Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis
  November 26, 2020 by Ramita Dewan
• ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation
  November 13, 2020 by Jin-Hui Hor
• Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
  July 9, 2020 by Timothy Miller
• Understanding the needs of people with ALS: a national survey of patients and caregivers
  May 13, 2020 by Kate T Brizzi
• Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
  May 10, 2020 by Michael Benatar
• Author Correction: Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells
  April 22, 2020 by Tomoyuki Koga
• Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72
  April 15, 2020 by Qiang Zhu
• Primary lateral sclerosis: consensus diagnostic criteria
  February 8, 2020 by Martin R Turner
• Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells
  January 30, 2020 by Tomoyuki Koga

• Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis
  November 26, 2020 by Ramita Dewan

2019

• Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology
  December 20, 2019 by Irit Reichenstein
• Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia
  November 1, 2019 by Jie Jiang
• Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia
  October 31, 2019 by Oliver H Tam
• Predicting disease specific spinal motor neurons and glia in sporadic ALS
  July 6, 2019 by Fabien Dachet
• Membralin deficiency dysregulates astrocytic glutamate homeostasis leading to ALS-like impairment
  May 22, 2019 by Lu-Lin Jiang
• A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis
  May 14, 2019 by Jeremy M Shefner
• Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis
  February 7, 2019 by Sara Bandres-Ciga
• Antisense RNA foci are associated with nucleoli and TDP-43 mislocalization in C9orf72-ALS/FTD: a quantitative study
  January 23, 2019 by Olubankole Aladesuyi Arogundade
• Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration
  January 16, 2019 by Ze'ev Melamed
• TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates
  December 19, 2018 by Florent Laferrière

• Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology
  December 20, 2019 by Irit Reichenstein
• Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis
  February 7, 2019 by Sara Bandres-Ciga

2018

• Properties of LINE-1 proteins and repeat element expression in the context of amyotrophic lateral sclerosis
  December 20, 2018 by Gavin C Pereira
• TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates
  December 19, 2018 by Florent Laferrière
• Clinical Reasoning: A 22-year-old man presenting with headache and right leg jerks
  November 7, 2018 by Alexander J Schupper
• Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins
  August 3, 2018 by Jens Mayer
• Astrocyte-derived Jagged-1 mitigates deleterious Notch signaling in amyotrophic lateral sclerosis
  July 17, 2018 by Annelies Nonneman
• Transcriptome-pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS
  June 9, 2018 by Florian Krach
• Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
  March 24, 2018 by Aude Nicolas
• Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial
  March 7, 2018 by Björn Oskarsson
• Elongator subunit 3 (ELP3) modifies ALS through tRNA modification
  February 8, 2018 by Andre Bento-Abreu
• Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis
  December 3, 2017 by Shahram Saberi
• Kinnier Wilson's puzzling features of amyotrophic lateral sclerosis
  November 11, 2017 by Martin R Turner

• Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
  March 24, 2018 by Aude Nicolas

2017

• Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis
  December 3, 2017 by Shahram Saberi
• Kinnier Wilson's puzzling features of amyotrophic lateral sclerosis
  November 11, 2017 by Martin R Turner
• Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
  October 26, 2017 by Csaba Konrad
• Mutant TDP-43 does not impair mitochondrial bioenergetics in vitro and in vivo
  May 10, 2017 by Hibiki Kawamata
• Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis
  March 31, 2017 by Dara Ditsworth
• Misfolded SOD1 is not a primary component of sporadic ALS
  March 2, 2017 by Sandrine Da Cruz
• TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis
  January 27, 2017 by Stephanie M Williams
• Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS)
  December 23, 2016 by Leslie I Grad
• Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal α-motoneurons in sporadic amyotrophic lateral sclerosis
  October 21, 2016 by Heiko Braak

• Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
• Mutant TDP-43 does not impair mitochondrial bioenergetics in vitro and in vivo

2016

• Sleep Apnea in Familial Dysautonomia: A Reflection of Apnea Pathogenesis
  November 19, 2016 by Jeremy E Orr
• Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal α-motoneurons in sporadic amyotrophic lateral sclerosis
  October 21, 2016 by Heiko Braak
• RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS
  August 6, 2016 by Yasushi Ito
• Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses
  July 6, 2016 by Katannya Kapeli
• Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs
  April 27, 2016 by Jie Jiang
• A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis
  March 17, 2016 by Jeremy M Shefner
• Neuregulin 1 confers neuroprotection in SOD1-linked amyotrophic lateral sclerosis mice via restoration of C-boutons of spinal motor neurons
  February 20, 2016 by Jurate Lasiene
• Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration
  February 19, 2016 by Drew L Sellers

• Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration
  February 19, 2016 by Drew L Sellers

2015

• Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants
  October 31, 2015 by Shahram Saberi
• Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS
  September 3, 2015 by Anna Emde
• Amyotrophic lateral sclerosis: Is the spinal fluid pathway involved in seeding and spread?
  July 30, 2015 by Richard Smith
• ALSUntangled No. 30: methylcobalamin
  July 24, 2015 by ALSUntangled Group
• A revision of the El Escorial criteria – 2015
  June 30, 2015 by Albert Ludolph
• ALSUntangled No. 29: MitoQ
  June 20, 2015 by ALSUntangled Group
• ALSUntangled No. 28: Acupuncture
  May 12, 2015 by ALSUntangled Group
• ALSUntangled No. 27: Precision Stem Cell
  March 27, 2015 by ALSUntangled Group
• Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways
  February 21, 2015 by Elizabeth T Cirulli
• Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes
  November 11, 2014 by Janet Cady

• Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS
  September 3, 2015 by Anna Emde
• Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways
  February 21, 2015 by Elizabeth T Cirulli

2014

• Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes
  November 11, 2014 by Janet Cady
• An α2-Na/K ATPase/α-adducin complex in astrocytes triggers non-cell autonomous neurodegeneration
  October 27, 2014 by Gilbert Gallardo
• Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis
  August 10, 2014 by John Ravits
• ALSUntangled no. 25: ursodiol
  June 28, 2014 by ALSUntangled Group
• ALSUntangled No. 24: Vitamin D
  April 3, 2014 by ALSUntangled Group
• TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis
  February 19, 2014 by Janet Cady
• Opportunities for improving therapy development in ALS
  January 30, 2014 by Lucie Bruijn
• Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS
  January 1, 2014 by Kathrin Meyer
• Activation of microglial neuregulin1 signaling in the corticospinal tracts of ALS patients with upper motor neuron signs
  November 16, 2013 by Fei Song
• ALSUntangled no. 23: the Rife machine and retroviruses
  November 14, 2013 by ALSUntangled Group

2013

• Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS
  January 1, 2014 by Kathrin Meyer
• Activation of microglial neuregulin1 signaling in the corticospinal tracts of ALS patients with upper motor neuron signs
  November 16, 2013 by Fei Song
• ALSUntangled no. 23: the Rife machine and retroviruses
  November 14, 2013 by ALSUntangled Group
• Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration
  October 31, 2013 by Clotilde Lagier-Tourenne
• Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion
  October 25, 2013 by Dhruv Sareen
• ALSUntangled No. 22: Propofol
  August 27, 2013 by ALSUntangled Group
• ALS Untangled No. 21: Fecal transplants
  July 23, 2013 by ALSUntangled Group
• Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis
  May 18, 2013 by John Ravits
• ALS Untangled No. 20: the Deanna protocol
  May 4, 2013 by ALSUntangled Group
• Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis
  April 20, 2013 by Matthew B Harms
• Opportunity and innovation in studying pre-symptomatic amyotrophic lateral sclerosis
  March 16, 2013 by Michael Benatar
• ALSUntangled No. 19: Sodium chlorite
  February 21, 2013 by ALSUntangled Group
• Controversies and priorities in amyotrophic lateral sclerosis
  February 19, 2013 by Martin R Turner
• ALSUntangled no. 18: apoaequorin (Prevagen)
  October 4, 2012 by ALSUntangled Group

2012

• ALSUntangled no. 18: apoaequorin (Prevagen)
  October 4, 2012 by ALSUntangled Group
• Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs
  October 2, 2012 by Clotilde Lagier-Tourenne
• ALS untangled No. 17: "when ALS is lyme"
  August 10, 2012 by ALSUntangled Group
• ALSUntangled No. 16: cannabis
  May 29, 2012 by ALSUntangled Group
• ALSUntangled 15: coconut Oil
  April 5, 2012 by ALSUntangled Group
• Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis
  January 18, 2012 by Fei Song
• ALSUntangled No. 14: Mototab
  January 5, 2012 by ALSUntangled Group

2011

• ALSUntangled 13: Bee venom
  October 26, 2011 by ALSUntangled Group
• ALSUntangled No. 11: Nu Tech Mediworld
  June 28, 2011 by ALSUntangled Group
• ALSUntangled No. 10: Luteolin and Lutimax
  May 7, 2011 by ALSUntangled Group
• ALSUntangled No. 9: Blue-green algae (Spirulina) as a treatment for ALS
  February 18, 2011 by ALSUntangled Group
• ALSUntangled No. 8: Low dose naltrexone for ALS
  December 23, 2010 by ALSUntangled Group

2010

• ALSUntangled No. 8: Low dose naltrexone for ALS
  December 23, 2010 by ALSUntangled Group
• ALSUntangled No. 7: Investigating hyperimmune goat serum (Aimspro) for ALS
  November 17, 2010 by ALSUntangled Group
• ALSUntangled No. 6: Investigating Marty Murray's method
  September 16, 2010 by ALSUntangled Group
• ALSUntangled No. 5: investigating the Stowe/Morales ALS Protocol
  June 22, 2010 by ALSUntangled Group
• ALSUntangled update 4: investigating the XCell-Center
  May 6, 2010 by ALSUntangled Group
• TDP-43 and ubiquitinated cytoplasmic aggregates in sporadic ALS are low frequency and widely distributed in the lower motor neuron columns independent of disease spread
  March 16, 2010 by Aaron Bodansky
• Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology
  October 30, 2009 by Stuart J Rabin
• No evidence of HIV pol gene in spinal cord tissues in sporadic ALS by real-time RT-PCR
  March 27, 2009 by Young Joo Kim

2009

• Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology
  October 30, 2009 by Stuart J Rabin
• ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration
  September 10, 2009 by John M Ravits

• ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration
  September 10, 2009 by John M Ravits

2008

• Current and future directions in genomics of amyotrophic lateral sclerosis
  July 16, 2008 by John Ravits
• An aggregate-inducing peripherin isoform generated through intron retention is upregulated in amyotrophic lateral sclerosis and associated with disease pathology
  February 22, 2008 by Shangxi Xiao

2007

• Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
  November 6, 2007 by Paul H Gordon
• Focality of upper and lower motor neuron degeneration at the clinical onset of ALS
  May 9, 2007 by John Ravits
• Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem
  May 9, 2007 by John Ravits
• Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations
  May 1, 2007 by Ian R A Mackenzie

2006

• A4V superoxide dismutase mutation in apparently sporadic ALS resembling neuralgic amyotrophy
  March 21, 2006 by M D Weiss

2005

• Amyotrophic lateral sclerosis microgenomics
  October 11, 2005 by John Ravits
• Sporadic amyotrophic lateral sclerosis: a hypothesis of persistent (non-lytic) enteroviral infection
  July 23, 2005 by John Ravits

2004

2003

• Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes
  September 26, 2003 by Peter M Andersen